Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396470 | 0.89 | AR (0.31) | AR | |
| SCHEMBL401154 | 0.78 | NPC1 (0.33) | AR | |
| SCHEMBL402700 | 0.78 | — | — | |
| SCHEMBL399810 | 0.78 | — | — | |
| SCHEMBL397934 | 0.76 | — | — | |
| SCHEMBL401088 | 0.76 | — | — | |
| SCHEMBL4066003 | 0.76 | — | — | |
| SCHEMBL397560 | 0.75 | HPGD (0.32) | — | |
| SCHEMBL400603 | 0.75 | TLR9 (0.36) | — | |
| SCHEMBL1154831 | 0.74 | IGF1R (0.34) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | claimed |
| EP-2250173-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-2250173-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | IGF1R, IGFBP3, INSR | AR 610/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.